![]() |
市場調查報告書
商品編碼
1492632
霍亂疫苗市場:按類型、管理方法、最終用戶、年齡層別分類 - 全球預測 2024-2030Cholera Vaccines Market by Type (Inactivated Vaccine, Live Attenuated Vaccine), Method of Administration (Injectable Vaccines, Oral Vaccines), End User, Age Group - Global Forecast 2024-2030 |
※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。
霍亂疫苗市場規模預計2023年為2.8642億美元,2024年達到3.0702億美元,預計2030年將達到4.6983億美元,複合年成長率為7.32%。
霍亂疫苗是生物製藥,旨在保護個人免受霍亂的侵害,霍亂是一種由霍亂弧菌引起的嚴重腹瀉疾病。這些疫苗會刺激人體的免疫反應,使其能夠在接觸霍亂弧菌後快速識別並抵抗霍亂弧菌。霍亂疫苗有兩種:口服疫苗和注射疫苗,每種疫苗的效果和免疫持續時間不同。由於全球前往霍亂流行地區的旅行增加,霍亂疫苗的使用大幅增加,增加了旅客採取預防措施的需要。此外,人們對全球衛生工作的認知和國際支持的提高也增加了對脆弱地區疫苗接種計劃的財政和後勤支援。然而,霍亂疫苗的推出面臨一些挑戰。在偏遠和資源匱乏地區分發和管理疫苗的物流挑戰阻礙了普及。此外,受年齡和是否存在預先存在的免疫力等因素影響,疫苗誘導的免疫力存在變異性,這使得不同人群中疫苗功效的測量變得複雜。儘管有這些挑戰,疫苗技術的進步,例如單劑量疫苗和溫度穩定製劑的開發,有可能顯著提高疫苗宣傳活動的實用性和有效性。此外,將霍亂疫苗接種計劃與其他公共衛生工作相結合可以加強整體疾病控制並促進受影響地區更永續的健康改善。
主要市場統計 | |
---|---|
基準年[2023] | 2.8642億美元 |
預計年份 [2024] | 30702萬美元 |
預測年份 [2030] | 46983萬美元 |
複合年成長率(%) | 7.32% |
區域洞察
霍亂疫苗市場由公共衛生需求和社會經濟條件決定,並在世界不同地區表現出獨特的特徵。在美國,來自霍亂流行地區和某些移民社區的旅客對它有需求。此外,該地區強大的醫療保健和衛生系統也有利於霍亂疫苗接種計畫。在歐洲,霍亂疫苗主要提供給前往流行地區的旅客和軍事相關人員。中東和非洲的霍亂風險和發病率很高,主要是由於衛生條件不佳和清潔水供應不足,因此需要霍亂疫苗。在亞太地區,由於南亞和東南亞霍亂盛行率很高,因此對霍亂疫苗的需求很高。印度和孟加拉等國家深受霍亂影響,是該地區需求的主要驅動力。意識的提高和政府控制霍亂疫情的努力也支持了這些疫苗的穩定消費。
FPNV定位矩陣
FPNV 定位矩陣對於評估霍亂疫苗市場供應商的定位至關重要。此矩陣提供了對供應商的全面評估,並檢查了與業務策略和產品滿意度相關的關鍵指標。這種詳細的評估使用戶能夠根據自己的要求做出明智的決定。根據評估結果,供應商被分為代表其成功程度的四個像限:前沿(F)、探路者(P)、利基(N)和重要(V)。
市場佔有率分析
市場佔有率分析是一種綜合工具,可以對霍亂疫苗市場供應商的現狀進行深入而詳細的評估。透過仔細比較和分析供應商的貢獻,您可以更深入地了解每個供應商的績效以及他們在爭奪市場佔有率時面臨的挑戰。這些貢獻包括整體收益、客戶群和其他重要指標。此外,該分析還提供了對該行業競爭性質的寶貴見解,包括在研究基準年期間觀察到的累積、分散主導地位和合併特徵等因素。有了這些詳細資訊,供應商可以做出更明智的決策並製定有效的策略,以在市場競爭中保持領先地位。
策略分析與建議
策略分析對於尋求在全球市場站穩腳跟的組織至關重要。對霍亂疫苗市場當前地位的全面評估使公司能夠做出符合其長期願望的明智決策。此關鍵評估涉及對組織的資源、能力和整體績效進行徹底分析,以確定核心優勢和需要改進的領域。
[199 Pages Report] The Cholera Vaccines Market size was estimated at USD 286.42 million in 2023 and expected to reach USD 307.02 million in 2024, at a CAGR 7.32% to reach USD 469.83 million by 2030.
Cholera vaccines are biological preparations designed to protect individuals from cholera, a severe diarrheal illness caused by the Vibrio cholerae bacteria. These vaccines stimulate the body's immune response, enabling it to quickly recognize and combat the cholera bacteria if exposed. There are several types of cholera vaccines available, including both oral and injectable forms, each with varying degrees of effectiveness and duration of immunity. The use of cholera vaccines has expanded considerably owing to the global increase in travel to areas where cholera is endemic, which has heightened the need for preventive measures among travelers. Further, growing awareness and international support for global health initiatives have increased funding and logistical support for vaccination programs in vulnerable regions. However, the deployment of cholera vaccines faces several challenges. Logistical difficulties in distributing and administering vaccines in remote or resource-limited areas hinder widespread coverage. Additionally, the variability in vaccine-induced immunity, which can be influenced by factors such as age and the presence of pre-existing immunity, complicates the measurement of vaccine effectiveness in different populations. Despite these challenges, advances in vaccine technology, such as the development of single-dose vaccines or temperature-stable formulations, could significantly improve the practicality and effectiveness of vaccination campaigns. Moreover, integrating cholera vaccination programs with other public health initiatives could enhance overall disease control and promote more sustainable health improvements in affected regions.
KEY MARKET STATISTICS | |
---|---|
Base Year [2023] | USD 286.42 million |
Estimated Year [2024] | USD 307.02 million |
Forecast Year [2030] | USD 469.83 million |
CAGR (%) | 7.32% |
Regional Insights
The cholera vaccine market exhibits distinct characteristics across various global regions, shaped by public health needs and socio-economic conditions. In America, there is demand among travelers and certain immigrant communities from cholera-endemic regions. Further, robust healthcare and sanitation systems across the region facilitate cholera vaccination programs. Europe has a significant adoption of cholera vaccines, majorly among travelers and military personnel deployed to endemic regions. The Middle East and Africa face higher risks and incidences of cholera, primarily attributed to poor sanitation and inadequate access to clean water, generating a need for cholera vaccines. Asia-Pacific observes a significant need for the cholera vaccine owing to higher prevalence rates in South and Southeast Asia. Countries such as India and Bangladesh are heavily impacted by cholera, largely driving the need in the region. The increasing awareness and government initiatives to control cholera outbreaks also support the steady consumption of these vaccines.
Market Insights
The market dynamics represent an ever-changing landscape of the Cholera Vaccines Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.
FPNV Positioning Matrix
The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Cholera Vaccines Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Cholera Vaccines Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Recent Developments
Strategic Technology Transfer in Cholera Vaccination: A Partnership Between IVI and Biological E. Limited
South Korea's International Vaccine Institute (IVI) has initiated a technology transfer to Biological E. Limited (BE), an Indian vaccine and pharmaceutical company. This collaboration involves IVI providing BE with the necessary technical information, know-how, and materials to manufacture the simplified oral cholera vaccine (OCV-S) in India. This partnership intends to enhance the availability of affordable cholera vaccines for both the Indian market and globally. [Published On: 2024-03-21]
Strategic Collaboration for Cholera Vaccine Production between GC Biopharma and Eubiologics
GC Biopharma, a South Korean biopharmaceutical company, has entered into a memorandum of understanding with Eubiologics to collaboratively produce the oral cholera vaccine, Euvichol. Under this agreement, Eubiologics will manage the bulk manufacturing phase of the vaccine, while GC Biopharma will handle the packaging tasks, including the bottling of the vaccine into vials, ensuring a streamlined process for vaccine supply. [Published On: 2023-08-28]
TechInvention Introduces Innovative Cholera Vaccine Packaging in India with Eubiologics Partnership
Mumbai-based TechInvention Lifecare, in collaboration with South Korea's Eubiologics Co., has introduced Euvichol-Plus, an oral cholera vaccine encased in a low-density polyethylene (LDPE) unidose pack. This innovative packaging solution addresses several issues associated with traditional glass vials, including risks of breakage and challenges in storage, transportation, handling, and disposal. [Published On: 2023-05-12]
Strategy Analysis & Recommendation
The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Cholera Vaccines Market. This critical assessment involves a thorough analysis of the organization's resources, capabilities, and overall performance to identify its core strengths and areas for improvement.
Key Company Profiles
The report delves into recent significant developments in the Cholera Vaccines Market, highlighting leading vendors and their innovative profiles. These include Astellas Pharma Inc., Beijing Minhai Biological Technology Co., Ltd., Bharat Biotech Ltd., Bio-Manguinhos, Biological E Ltd, BioVac by Ceva Sante Animale, Emergent BioSolutions Inc., GlaxoSmithKline plc, Haffkine Bio-Pharmaceutical Corporation Ltd, Incepta Pharmaceuticals Ltd., Merck & Co. Inc, Panacea Biotec Ltd, Sanofi S.A., SK Inc., Techinvention Lifecare Pvt. Ltd., and Valneva SE.
Market Segmentation & Coverage